{{expand|time=2017-12-24T17:24:27+00:00}}
{{wwv}}
{{medical}}
{{Drugbox
| verifiedrevid = 464405524
| IUPAC_name = 4-[4-<nowiki>[[</nowiki>4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]<br>phenoxy]-''N''-methyl-pyridine-2-carboxamide
| image = Sorafenib2DACS.svg
| width = 300
| image2 = Sorafenib3Dan.gif
| width2 = 250

<!--Clinical data-->
| tradename = Nexavar
| Drugs.com = {{drugs.com|monograph|nexavar}}
| MedlinePlus = a607051
| licence_EU = Nexavar
| licence_US = Sorafenib
| pregnancy_AU = D
| pregnancy_US = D
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 38–49%
| protein_bound = 99.5%
| metabolism = [[Liver|Hepatic]] [[redox|oxidation]] and [[glucuronidation|glucuronidation]] ([[CYP3A4|CYP3A4]] & [[UGT1A9|UGT1A9]]-mediated)
| elimination_half-life = 25–48 hours
| excretion = Faeces (77%) and urine (19%)

<!--Identifiers-->
| IUPHAR_ligand = 5711
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 284461-73-0
| ATC_prefix = L01
| ATC_suffix = XE05
| PubChem = 216239
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00398
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 187440
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9ZOQ3TZI87
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08524
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50924
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1336
| PDB_ligand = BAX

<!--Chemical data-->
| C=21 | H=16 | Cl=1 | F=3 | N=4 | O=3
| molecular_weight = 464.825 g/mol
| smiles = CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MLDQJTXFUGDVEO-UHFFFAOYSA-N
| synonyms = Nexavar<br>Sorafenib tosylate
}}
'''索拉非尼'''（'''Sorafenib'''），商品名'''蕾莎瓦'''（'''Nexavar®''' ）
<ref>{{cite web|url=http://www.kfsyscc.org/cancer/cancer-treatment/med/info/Sorafenib|title=蕾莎瓦膜衣錠|publisher=和信治癌中心醫院|date=2010-11-20|accessdate=}}</ref>
，是美國[[拜耳|拜耳股份有限公司]]的[[專利藥|專利藥]]，經[[美國食品藥物管理局|美國食品藥物管理局]]核可用於治療[[腎細胞癌|腎細胞癌]]及[[肝癌|肝癌]]<ref>{{cite web|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm|title=FDA Approves Nexavar for Patients with Inoperable Liver Cancer|publisher=FDA.gov|date=2007-11-19|accessdate=}}</ref>。2012年8月1日，台灣[[健保局|健保局]]通過健保給付蕾莎瓦，支付價每顆1092元，平均每月藥費13萬元<ref>{{cite web|url=http://tw.news.yahoo.com/%E8%82%9D%E7%99%8C%E8%97%A5%E8%95%BE%E8%8E%8E%E7%93%A6-%E4%BB%8A%E8%B5%B7%E7%B4%8D%E5%85%A5%E5%81%A5%E4%BF%9D%E7%B5%A6%E4%BB%98-160951241.html|title=肝癌藥蕾莎瓦 今起納入健保給付|publisher=台灣新生報|date=2012-08-01|accessdate=}}</ref><ref>{{cite web|url=http://www.show.org.tw/headline_detail.asp?no=2386|title=蕾莎瓦（Sorafenib）—肝癌治療的新希望|publisher=秀傳醫療體系|date=2009-05-04|accessdate=|deadurl=yes|archiveurl=https://web.archive.org/web/20160305080734/http://www.show.org.tw/headline_detail.asp?no=2386|archivedate=2016-03-05}}</ref>。

==參考資料==
{{reflist}}
{{Extracellular chemotherapeutic agents}}


[[Category:脲|Category:脲]]
[[分類:受体酪氨酸激酶抑制剂|分類:受体酪氨酸激酶抑制剂]]